GlossaryPod – Equity & Equality
ruth brice2021-05-14T10:25:33+00:00
14
05, 2021
20
12, 2019
Society wants fair, not utilitarian, approaches to value
ruth brice2019-12-20T07:38:19+00:00Paper of the Week: 20th December 2019 This week’s blog is brought to you by: Dr Tim Wilson Full reference and title from the journal: Funding orphan medicinal products beyond price: sustaining an ecosystem , Author- De Sola-Morales, Oriol, The European Journal of Health Economics (2019) 20:1283–1286 Web link to paper: https://doi.org/10.1007/s10198-019-01047-0 Authors conclusion: “it is not the individual price that matters, but whether the overall budget impact is perceived as acceptable and that manufacturers have an accept- able profit.” 3V bottom line: Ideally, a decision whether a treatment or intervention should be used in a health system is largely be driven by value and values. In the case of effective but expensive treatments for rare conditions, societal [...]
18
11, 2019
Can equity be measured as accurately as quality?
ruth brice2019-11-18T11:02:01+00:00Paper of the Week: 18th November 2019 This week’s blog is brought to you by: Professor Sir Muir Gray Full reference and title from the journal: Whitehead J. et al (2019), How can the spatial equity of health services be defined and measured? A systematic review of spatial equity definitions and methods, Journal of Health Services Research & Policy Vol. 24(4) 270–278, DOI: 10.1177/1355819619837292. https://journals.sagepub.com/doi/abs/10.1177/1355819619837292?journalCode=hsrb Authors conclusion There appeared to be general agreement that spatial equity is difficult to define…Although a wide variety of methods were used, the Gini coefficient was identified as the most common method of spatial equity analysis. 3V bottom line Equity is difficult to measure accurately but it should be included in every report [...]
30
09, 2019
Paper of the Week: 30th September 2019 – Overuse of low value dependence forming medications is common (and more likely if you live in a deprived area)
ruth brice2019-09-30T08:56:49+00:00This week’s blog is brought to you by: Professor Alf Collins, Clinical Director for Personalised Care, NHS England and Improvement. Full reference and title from the journal: Link to Public Health England Prescribed Medicines Review - Click here Authors conclusion In England in the year 2017 to 2018, 1-in-4 adults in England were prescribed benzodiazepines, z-drugs, gabapentinoids, opioids for chronic non-cancer pain, or antidepressants. There are large variations in standardised rates of prescribing at the level of CCGs. The rate of prescribing and the time receiving a prescription increase with deprivation. Longer-term prescribing is widespread. Aside from antidepressants, the medications reviewed are all licensed and indicated for (usually) short-term treatment of acute conditions. Patients described not being [...]
28
11, 2018
Paper of the week 28.11.18: The view of experts on initiatives to be undertaken to promote equity
ruth brice2018-11-29T15:19:45+00:00Reference: The view of experts on initiatives to be undertaken to promote equity in the access to orphan drugs and specialised care for rare diseases in Spain: A Delphi consensus. Torrent-Farnell at al 2018 This week’s paper of the week is brought to you by Professor Sir Muir Gray, 3V Executive Director. Bottom line Delivering equity for rare diseases in healthcare is difficult, with no simple solution. What is required is a process that adopts “reasonableness”. Further, despite what this paper says, structural change is not required to improve equity, the creation of networks is required, like those for neurofibromatosis type 2 in England Implications for value improvement This project focused on a common problem, often overlooked – [...]